cyad-101: a first non-gene edited allogeneic car t cell · twitter : @celyadsa • linkedin :...
TRANSCRIPT
CYAD-101: A first non-gene
edited allogeneic CAR T cell
S I T C 2 0 1 8
No
ve
mb
er
9,
20
18
Forward-Looking Statements
This presentation may contain forward-looking statements, including statements regarding the safety and efficacy of CYAD-01 and the new mAbmanufacturing method used to manufacture this drug product candidate; statements concerning the ongoing and planned clinical development of CYAD-01.Forward-looking statements may involve known and unknown risks, uncertainties and other factors which might cause actual results, financial condition andliquidity, performance or achievements of Celyad, or industry results, to differ materially from those expressed or implied by such forward-lookingstatements. In particular it should be noted that the interim data summarized above are preliminary in nature. The THINK trial is not complete. There is limiteddata concerning safety and clinical activity following treatment with the CYAD-01 drug product candidate. These results may not be repeated or observed inongoing or future studies involving the CYAD-01 drug product candidate. These forward-looking statements are further qualified by important factors andrisks, which could cause actual results to differ materially from those in the forward-looking statements, including statements about: the initiation, timing,progress and results of our preclinical studies and clinical trials, and our research and development programs; our ability to advance drug product candidatesinto, and successfully complete, clinical trials; our ability to successfully manufacture drug product for our clinical trials, including with our new mAbmanufacturing process and with respect to manufacturing drug product with the desired number of T cells under our clinical trial protocols; our reliance on thesuccess of our drug product candidates, including our dependence on the regulatory approval of CYAD-01 in the United States and Europe and subsequentcommercial success of CYAD-01, both of which may never occur; the timing or likelihood of regulatory filings and approvals; our ability to develop sales andmarketing capabilities; the commercialization of our drug product candidates, if approved; the pricing and reimbursement of our drug product candidates, ifapproved; the implementation of our business model, strategic plans for our business, drug product candidates and technology; the scope of protection weare able to establish and maintain for intellectual property rights covering our drug product candidates and technology; our ability to operate our businesswithout infringing, misappropriating or otherwise violating the intellectual property rights and proprietary technology of third parties; cost associated withenforcing or defending intellectual property infringement, misappropriation or violation; product liability; and other claims; regulatory development in theUnited States, the European Union, and other jurisdictions; estimates of our expenses, future revenues, capital requirements and our needs for additionalfinancing; the potential benefits of strategic collaboration agreements and our ability to enter into strategic arrangements; our ability to maintain andestablish collaborations or obtain additional grant funding; the rate and degree of market acceptance of our drug product candidates, if approved; ourfinancial performance; developments relating to our competitors and our industry, including competing therapies and statements regarding future revenue,hiring plans, expenses, capital expenditures, capital requirements and share performance. A further list and description of these risks, uncertainties and otherrisks can be found in Celyad’s U.S. Securities and Exchange Commission (SEC) filings and reports, including in its Annual Report on Form 20-F filed with theSEC on April 6, 2018 and subsequent filings and reports by Celyad. Given these uncertainties, the reader is advised not to place any undue reliance on suchforward-looking statements. These forward-looking statements speak only as of the date of publication of this document and Celyad’s actual results maydiffer materially from those expressed or implied by these forward-looking statements. Celyad expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances onwhich any such statement is based, unless required by law or regulation.
2
CYAD-101: A non-gene edited allogeneic CAR T cell using TIM technology
3
Va Vb
Ca Cb
+++
CD
3ε
CD
3γ
CD
3ε
CD
3δ
-- --
TIM
TIM
CD
3ζ
CD
3ζ
ITA
Ms
S I T C 2 0 1 8 – C Y A D - 1 0 1
Donor Patient
Healthy tissues
GvHDTCR
CYAD-101: an allogeneic CAR T cell based on NKG2D receptor
S I T C 2 0 1 8 – C Y A D - 1 0 1
4
• Retroviral transduction of :
• TCR inhibitory molecule (TIM)
• Co-expression of a Second generation CAR using endogenous DAP10 as co-stimulator
TIM incorporating TCR complex NKG2D CAR
C T R ( t C D 1 9 ) C Y A D - 1 0 1
0 . 0
0 . 2
0 . 4
0 . 6
0 . 8
IFN
-
(n
g/
ml)
* *
0 2 0 4 0 6 0
0
5 0
1 0 0
D a y s a f t e r i n j e c t i o n
Pe
rc
en
t s
ur
viv
al
C T R ( t C D 1 9 )
C Y A D - 1 0 1
* * *
TIM impairs CYAD-101 CAR T alloreactivity in vitro and in vivo
5
CYAD-101
NSG mice (n=9)
S I T C 2 0 1 8 – C Y A D - 1 0 1
OKT3 TCR activation
n=12
5 1 0 1 5 2 0 2 5 3 0
0
5 1 01 0
1 1 01 1
1 . 5 1 01 1
D a y s p o s t i n f u s i o n
Bio
lum
ine
sc
en
ce
(p
ho
to
ns
/ s
ec
/ m
m2
)
C T R ( t C D 1 9 )
C Y A D - 1 0 1
* * *
* * *
0 1 0 2 0 3 0 4 0 5 0
0
5 0
1 0 0
D a y s a f t e r i n j e c t i o n
Pe
rc
en
t s
ur
viv
al
C T R ( t C D 1 9 )
C Y A D - 1 0 1* * * *
CYAD-101 is potent against NKG2D ligands expressing tumour in vivo
6
S I T C 2 0 1 8 – C Y A D - 1 0 1
0.2x106
HCT116
D0 D7
10x106
CYAD-101
D14
10x106
CYAD-101
D21
10x106
CYAD-101
Future of CYAD-101
7
S I T C 2 0 1 8 – C Y A D - 1 0 1
• CYAD-101 CAR T cells
• Inhibition of GvHD
• Effective CAR activity
• Phase I clinical study
• Second generation allogeneic platform based on shRNAs (P220)
Contact
Follow us
Twitter : @CelyadSA • Linkedin : @Celyad
Thank you !
W W W . C E L Y A D . C O M
Abstract Poster Number: P213CYAD-101: an allogeneic NKG2D CAR T cell therapy using a TCR inhibitory molecule
Poster location: Hall EPoster presentation hours: Friday, Nov. 9, from 12:45 – 2:15 p.m. and 6:30 – 8 p.m.
